Free Trial
NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$14.50 -0.21 (-1.43%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$14.54 +0.04 (+0.24%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$14.48
$15.61
50-Day Range
$9.37
$16.55
52-Week Range
$8.91
$28.09
Volume
728,148 shs
Average Volume
480,490 shs
Market Capitalization
$790.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.43
Consensus Rating
Moderate Buy

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

Wedbush Lifts Earnings Estimates for Bicara Therapeutics
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Bicara: Innovative Precision Tumor Targeting
Bicara Therapeutics initiated with an Underweight at Wells Fargo
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 16.8% and is now trading at $14.50.
View the best growth stocks for 2025 here
.

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings results on Thursday, March, 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.08.

Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

Bicara Therapeutics' lock-up period expired on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Bicara Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.08%), Victory Capital Management Inc. (0.06%), Rhumbline Advisers (0.04%) and GAMMA Investing LLC (0.01%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/27/2025
Today
5/03/2025
Next Earnings (Estimated)
6/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.43
High Stock Price Target
$48.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+123.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$790.58 million
Optionable
N/A
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners